StocksDiva Bio Bin

[StocksDiva]

PSTI Pluristem Therapeutics issues letter to shareholders highlighting significant achievements on several fronts () 4.07 : CO announces it issued a letter to shareholders that provides an overview of the numerous milestones recently achieved by the company. The letter can be found on the company's website. Highlights include: (-) Raised net $34 million in a secondary offering, bringing the company's cash position to approximately $70 million, with no debt; (-) Targeting future clinical trials in Bone Marrow Transplant failure indications, following the improvement of clinical condition and hematological counts after treatment of critically ill patients under a compassionate use program at the Hadassah Medical Center in Jerusalem; (-) Began FDA-approved Phase II clinical trials in the U.S. for Intermittent Claudication; (-) Received approval for Phase I/II clinical trial in muscle injury in Germany; (-) Received approval from the Indian Ministry of Health to begin Phase II clinical trials in Buerger's Disease patients; (-) Filed for Orphan Drug Status with the U.S. FDA for Aplastic Anemia; (-) Optimizing manufacturing processes for commercial scale up; (-) Building a new state-of-the-art manufacturing GMP facility in Israel suitable for large-scale production; and (-) Pursuing new indications and fields of research in lung disease and acute radiation syndrome